Laboratorios Farma traded at 78.55 this Saturday February 21st, decreasing 0.50 or 0.63 percent since the previous trading session. Looking back, over the last four weeks, Laboratorios Farma lost 6.73 percent. Over the last 12 months, its price rose by 42.43 percent. Looking ahead, we forecast Laboratorios Farma to be priced at 76.56 by the end of this quarter and at 70.48 in one year, according to Trading Economics global macro models projections and analysts expectations.
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.